Finance

Lists
Why is INSM up 2.62%?
Dive Deeper
INSM:NASDAQ
Insmed Inc
$121.16
+2.62%
(+3.09) 1D
$121.16
0.00% (0.00)
After hours
Closed: Nov 13, 4:00:00 PM GMT-5  ·   USD
All symbols
SymbolPriceChange% Change
Generating top insights for INSM...
Open
$118.18
High
$121.54
Low
$116.97
Mkt. cap
26.58B
Avg. vol.
3.68M
Volume
1.54M
52-wk high
$212.75
52-wk low
$90.39
EPS
-$2.82
Beta
0.83
Shares outstanding
219.38M
No. of employees
2K
Open
$118.18
High
$121.54
Low
$116.97
Mkt. cap
26.58B
Avg. vol.
3.68M
Volume
1.54M
52-wk high
$212.75
52-wk low
$90.39
EPS
-$2.82
Beta
0.83
Shares outstanding
219.38M
No. of employees
2K
News stories
From web sources and news partners
About Insmed Inc
CEOWilliam H. Lewis
Employees1.66K
Founded1988
HeadquartersBridgewater, New Jersey, United States
SectorHealth Care
IndustryBiotechnology
Websiteinsmed.com
Analyst ratings
Based on 17 analysts giving stock ratings to INSM in the past 3 months
Strong buy
Buy
16
Hold
1
Sell
0
12-month forecast
Based on 17 Wall Street analysts offering 12 month price targets for INSM in the last 3 months.
Highest
Current $121.16
$220.00 (+81.58%)
Average
$190.50 (+57.23%)
Lowest
$158.00 (+30.41%)
Analyst
Recommendation
Action
Price target
Projected
Date
Gavin Clark-Gartner
Evercore ISI
Buy
Maintained
$170.00
+40.3%
11/05/2026
Matthew Caufield
H.C. Wainwright
Buy
Initiated
$220.00
+81.6%
11/04/2026
Graig Suvannavejh
Mizuho Securities
Buy
Maintained
$158.00
+30.4%
11/03/2026
Unknown Analyst
Leerink Partners
Buy
Maintained
$198.00
+63.4%
11/02/2026
Vamil Divan
Guggenheim
Buy
Reiterated
$201.00
+65.9%
11/01/2026
Eliana Merle
Barclays
Buy
Maintained
$207.00
+70.8%
11/02/2026
Conor MacKay
BMO Capital
Buy
Maintained
$192.00
+58.5%
11/02/2026
Maxwell Skor
Morgan Stanley
Buy
Reiterated
$213.00
+75.8%
10/30/2026
Andrea Newkirk
Goldman Sachs
Buy
Maintained
$194.00
+60.1%
10/30/2026
Ashwani Verma
UBS
Buy
Maintained
$172.00
+42%
10/30/2026
Leonid Timashev
RBC Capital
Buy
Reiterated
$195.00
+60.9%
10/29/2026
Adam Walsh
Roth MKM
Buy
Maintained
$204.00
+68.4%
10/29/2026
Andrew Fein
H.C. Wainwright
Buy
Reiterated
$220.00
+81.6%
10/27/2026
Tiago Fauth
Raymond James
Buy
Maintained
$173.00
+42.8%
10/20/2026
Benjamin Burnett
Wells Fargo
Buy
Reiterated
$169.00
+39.5%
10/13/2026
Jason Zemansky
Bank of America Securities
Buy
Reiterated
$207.00
+70.8%
10/12/2026
Andy Chen
Wolfe Research
Hold
Downgraded
-
-
10/12/2026
Jessica Fye
J.P. Morgan
Buy
Reiterated
$175.00
+44.4%
09/28/2026
Danielle Brill
Truist Financial
Buy
Reiterated
$195.00
+60.9%
08/10/2026
Olivia Brayer
Cantor Fitzgerald
Buy
Maintained
$235.00
+94%
08/06/2026
Ritu Baral
TD Cowen
Buy
Maintained
$243.00
+100.6%
08/06/2026
Faisal Khurshid
Jefferies
Buy
Maintained
$175.00
+44.4%
08/06/2026
Matt Phipps
William Blair
Buy
Maintained
-
-
08/06/2026
Evan Seigerman
BMO Capital
Buy
Initiated
$192.00
+58.5%
07/21/2026
Unknown Analyst
BMO Capital
Buy
Initiated
$192.00
+58.5%
07/20/2026
Stephen Willey
Stifel Nicolaus
Buy
Maintained
$200.00
+65.1%
07/17/2026
Unknown Analyst
Jefferies
Buy
Maintained
$175.00
+44.4%
06/23/2026
Tyler Van Buren
TD Cowen
Buy
Maintained
$243.00
+100.6%
05/20/2026
Unknown Analyst
J.P. Morgan
Buy
Maintained
$180.00
+48.6%
05/20/2026
Unknown Analyst
Evercore ISI
Buy
Maintained
$162.00
+33.7%
05/15/2026
Unknown Analyst
Raymond James
Buy
Initiated
$200.00
+65.1%
04/09/2026
Last report
Oct 29, 2026
Fiscal period
Q3 2026
-$0.46 / -$0.37
-23.69%miss
Revenue / Est. (USD)
524.43M / 500.73M
+4.73%beat
Fiscal Q3 2026 earnings call
Waiting for the earnings call
At a glance
Insights from the latest news and reports
Previous reportsAll values in USD
Loading Previous Earnings...
Revenue
Net income
All values in USD
Dec 2025
Mar 2026
Jun 2026
Sep 2026
Revenue
263.84M
305.96M
425.49M
524.43M
Cost of goods sold
44.22M
47.42M
67.21M
78.22M
Cost of revenue
44.22M
47.42M
67.21M
78.22M
Research and development expenses
254.91M
209.48M
210.03M
269.96M
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
212.48M
247.26M
247.47M
253.03M
Operating expense
469.33M
458.82M
459.58M
528.04M
Total operating expenses
513.55M
506.24M
526.79M
606.26M
Operating income
-249.71M
-200.28M
-101.31M
-81.83M
Other non operating income
-1.82M
-736.00K
-531.00K
1.06M
EBT including unusual items
-326.93M
-162.10M
-11.37M
-97.65M
EBT excluding unusual items
-256.89M
-209.06M
-111.13M
-90.11M
Income tax expense
1.55M
1.46M
1.87M
2.67M
Effective tax rate
-0.47%
-0.90%
-16.43%
-2.73%
Other operating expenses
-
-
-
-
Net income
-328.48M
-163.56M
-13.24M
-100.32M
Net profit margin
-124.50%
-53.46%
-3.11%
-19.13%
Earnings per share
-1.54
-0.76
-0.06
-0.46
Interest and investment income
15.24M
12.04M
10.98M
11.07M
Interest expense
-20.60M
-20.08M
-20.27M
-20.41M
Net interest expenses
-5.36M
-8.04M
-9.29M
-9.34M
Depreciation and amortization charges
-
-
-
-
EBITDA
-244.68M
-195.80M
-96.58M
-73.97M
Gain or loss from assets sale
-
-
-
-
Insider transactions
Insider transactions data is drawn from third-party sources. Learn more
Insider
Position
Type
Date
Shares
Amount
Page 1
Upcoming events
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer
Google apps